Related Experiment Videos

Wild-type p53-mediated induction of rat mdr1b expression by the anticancer drug daunorubicin

G Zhou1, M T Kuo

  • 1Department of Molecular Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

Insights

Wild-type p53 up-regulates the rat mdr1b gene, a key factor in multidrug resistance. A specific p53-binding site in the mdr1b promoter is crucial for this induction by anticancer drugs like daunorubicin.

Area of Science:

  • Molecular Biology
  • Genetics
  • Cancer Research

Background:

  • The multidrug resistance (MDR) phenotype in animal cells is linked to P-glycoprotein expression from the mdr gene family.
  • MDR gene expression can be triggered by various external factors, including cytotoxic drugs and chemical carcinogens, but the underlying mechanisms remain unclear.

Purpose of the Study:

  • To investigate the mechanisms of inducible mdr gene expression.
  • To identify the role of p53 in the regulation of the rat mdr1b gene.

Main Methods:

  • Reporter assays were used to analyze the rat mdr1b promoter activity.
  • Site-directed mutagenesis identified a critical p53-binding site.
  • Western blotting and quantitative PCR assessed endogenous mdr1b expression.

Main Results:

  • Anticancer drug daunorubicin induces the expression of rat mdr1b.
  • A functional p53-binding site (-199 to -180) in the rat mdr1b promoter is essential for basal and daunorubicin-inducible activity.
  • Wild-type p53 significantly enhances both promoter function and endogenous rat mdr1b expression.

Conclusions:

  • This study reveals a direct role for wild-type p53 in the transcriptional regulation of the rat mdr1b gene via a specific promoter-binding site.
  • The findings provide crucial insights into the inducible expression of mdr genes in response to DNA-damaging agents, including anticancer drugs and carcinogens.

Related Concept Videos